Metabolism modulators in sepsis: The abnormal pituitary response

Critical Care Medicine

Volumn 35, Issue 9 SUPPL., 2007, Pages

  Maxime, Virginie ^a   Siami, Shidasp ^a   Annane, Djillali ^a  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Apoptosis; Autonomic nervous system; Cytokines; Hypothalamus; Neurohormones; Neurons; Nitric oxide; Organ failure; Pituitary gland; Sepsis

Indexed keywords

AUTACOID; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; FOLLITROPIN; GLUCOCORTICOID; GONADORELIN; GROWTH HORMONE; HYDROCORTISONE; INDUCIBLE NITRIC OXIDE SYNTHASE; LUTEINIZING HORMONE; MINERALOCORTICOID; NITRIC OXIDE; PRALMORELIN; PROLACTIN; PROTIRELIN; THYROID HORMONE; THYROTROPIN; VASOPRESSIN;

AUTONOMIC NERVOUS SYSTEM; CLINICAL FEATURE; CONFERENCE PAPER; DEATH; ENZYME ACTIVATION; ENZYME INHIBITION; FEEDBACK SYSTEM; GROWTH HORMONE RELEASE; HEART PERFORMANCE; HEMODYNAMICS; HORMONE RELEASE; HUMAN; HYPOPHYSIS; HYPOPHYSIS FUNCTION; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOCOMPETENT CELL; INFLAMMATION; KIDNEY FUNCTION; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; MEDIATOR; METABOLISM; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SEPSIS; SEPTIC SHOCK; STIMULATION; SYSTEMATIC REVIEW; VASCULAR RESISTANCE;

CYTOKINES; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NITRIC OXIDE; PITUITARY GLAND; PITUITARY HORMONES; SEPSIS;

EID: 34548180621     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000279097.67263.52     Document Type: Conference Paper

References (59)

1. Chrousos GP: The stress response and immune function: Clinical implications. The 1999 Novera H. Spector Lecture. Ann NY Acad Sci 2000; 917:38-67
2. McConnel EM: The arterial blood supply of the human hypophysis cerebri. Anat Rec 1953; 115:175-203
3. Jones TH, Brown BL, Dobson PR: Paracrine control of anterior pituitary hormone secretion. J Endocrinol 1990; 127:5-13
4. Palkovits M: Distribution of neuropeptides in the central nervous system: A review of biochemical mapping studies. Prog Neurobiol 1984; 23:151-189
5. Porter JC, Sisom JF, Arita J, et al: The hypothalamic-hypophysial vasculature and its relationship to secretory cells of the hypothalamus and pituitary gland. Vitam Horm 1983; 40:145-174
6. Banks WA, Kastin AJ, Huang W, et al: Leptin enters the brain by a saturable system independent of insulin. Peptides 1996; 17:305-311
7. Koenig JI: Presence of cytokines in the hypothalamic-pituitary axis. Prog Neuroendocrinoimmunol 1991; 4:143-153
8. Spangelo BL, MacLeod RM, Isakson PC: Production of interleukin-6 by anterior pituitary cells in vitro. Endocrinology 1990; 126:582-586
9. Sharshar T, Annane D, Lorin de la Grandmaison G, et al: The neuropathology of septic shock. Brain Pathol 2004; 14:21-33
10. McCann SM, Kimura M, Karanth S, et al: The mechanism of action of cytokines to control the release of hypothalamic and pituitary hormones in infection. Ann NY Acad Sci 2000; 917:4-18
11. Sharshar T, Gray F, Lorin de la Grandmaison G, et al: Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock. Lancet 2003; 362:1799-1805
12. Wong ML, Bongiorno PB, Rettori V, et al: Interleukin (IL) 1b, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: Pathophysiological implications. Proc Natl Acad Sci U S A 1997; 93:227-232
13. Lyson K, McCann SM. Involvement of arachidonic acid cascade pathways in interleukin-6 stimulated corticotropin-releasing factor release in vitro. Neuroendocrinology 1992; 55:708-713
14. Rettori V, Dees WL, Hiney JK, et al: An interleukin-1alpha-like neuronal system in the preoptic-hypothalamic region and its induction by bacterial lipopolysaccharide in concentrations which alter pituitary hormone release. Neuroimmunomodulation 1994; 1:251-258
15. Karanth S, Lyson K, McCann SM: Role of nitric oxide in interleukin 2 induced corticotropin-releasing factor release from incubated hypothalami. Proc Nat Acad Sci USA 1993; 90:3383-3387
16. Karanth S, Lyson K, McCann SM: Effects of cholinergic agonists and antagonists on interleukin-2-induced corticotropin-releasing hormone release from the mediobasal hypothalamus. Neuroimmunomodulation 1999; 6:168-174
17. Parkes D, Kasckow J, Vale W: Carbon monoxide modulates secretion of corticotropinreleasing factor (CRF) from rat hypothalamic cell cultures. Brain Res 1993; 646:315-318
18. Pozzoli G, Mancuso C, Mirtella A, et al: Carbon monoxide as a novel neuroendocrine modulator: Inhibition of stimulated corticotropin-releasing hormone release from acute rat hypothalamic explants. Endocrinology 1994; 135:2314-2317
19. Kostoglou-Athanassiou I, Forsling ML, Navarra P, et al: Oxytocin release is inhibited by the generation of carbon monoxide from the rat hypothalamus-further evidence for carbon monoxide as a neuromodulator. Mol Brain Res 1996; 42:301-306
20. Dello Russo C, Tringali G, Ragazzoni N, et al: Evidence that hydrogen sulfide can modulate hypothalamo-pituitary-adrenal axis function: In vitro and in vivo studies in the rat. J Neuroendocrinol 2000; 12:225-233
21. Prigent H, Maxime V, Annane D: Science review: Mechanisms of impaired adrenal function in sepsis and molecular actions of glucocorticoids. Crit Care 2004; 8:243-252
22. Melby JC, Spink WW: Comparative studies on adrenal cortical function and cortisol metabolism in healthy adults and in patients with shock due to infection. J Clin Invest 1958; 37:1791-1798
23. Annane D, Maxime V, Ibrahim F, et al: Diagnosis of adrenal insufficiency in severe sepsis and septic shock. Am J Respir Crit Care Med 2006; 174:1319-1326
24. Annane D, Sébille V, Bellissant E, et al: Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med 2006; 34:22-30
25. Oelkers W: Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism. N Engl J Med 1989; 321:492-496
26. Rothwell PM, Udwadia ZF, Lawler PG: Cortisol response to corticotropin and survival in septic shock. Lancet 1991; 337:582-583
27. Annane D, Sébille V, Troché G, et al: A three-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000; 283:1038-1045
28. Dadoun F, Velut JG, Guillaume V, et al: Combined hypervolemia and hypoosmolality alter hypothalamic-pituitary adrenal axis response to endotoxin stimulation. Neuroendocrinology 1999; 69:352-359
29. Raff H: Glucocorticoids inhibition of neurohypophysial vasopressin secretion. Am J Physiol 1987; 252:R635-R644
30. Sharshar T, Carlier R, Blanchard A, et al: Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002; 30:497-500
31. Landry DW, Levin HR, Gallant EM, et al: Vasopressin deficiency contributes to the dilatation of septic shock. Circulation 1997; 95:1122-1125
32. Holmes CL, Patel BM, Russell JA, et al: Physiology of vasopressin relevant to management of septic shock. Chest 2001; 120:989-1002
33. Sharshar T, Blanchard A, Paillard M, et al: Circulating vasopressin levels in septic shock. Crit Care Med 2003; 31:1752-1758
34. Auernhammer CJ, Feldmeier H, Nass R, et al: Insulin-like growth factor I is an independent coregulatory modulator of natural killer (NK) cell activity. Endocrinology 1996; 137:5332-5336
35. Ross R, Miell J, Freeman E, et al: Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I. Clin Endocrinol (Oxf) 1991; 35:47-54
36. Hermansson M, Wickelgren RB, Hammarqvist F, et al: Measurement of human growth hormone receptor messenger ribonucleic acid by a quantitative polymerase chain reaction- based assay: Demonstration of reduced expression after elective surgery. J Clin Endocrinol Metab 1997; 82:421-428
37. Van den Berghe G, de Zegher F, Lauwers P, et al: Growth hormone secretion in critical illness: Effect of dopamine. J Clin Endocrinol Metab 1994; 79:1141-1146
38. Van den Berghe G, de Zegher F, Veldhuis JD, et al: The somatotropic axis in critical illness: Effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. J Clin Endocrinol Metab 1997; 82:590-599
39. De Groot LJ: Dangerous dogmas in medicine: The nonthyroidal illness syndrome. J Clin Endocrinol Metab 1999; 84:151-164
40. Romijn JA, Wiersinga WM: Decreased nocturnal surge of thyrotropin in nonthyroidal illness. J Clin Endocrinol Metab 1990; 70:35-42
41. Michalaki M, Vagenakis AG, Makri M, et al: Dissociation of the early decline in serum T(3) concentration and serum IL-6 rise and TNF-alpha in nonthyroidal illness syndrome induced by abdominal surgery. J Clin Endocrinol Metab 2001; 86:4198-4205
42. De Jongh FE, Jobsis AC, Elte JW: Thyroid morphology in lethal non-thyroidal illness: A post-mortem study. Eur J Endocrinol 2001; 144:221-226
43. Van den Berghe G, de Zegher F, Baxter RC, et al: Neuroendocrinology of prolonged critical illness: Effects of exogenous thyrotropinreleasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab 1998; 83:309-319
44. Fliers E, Guldenaar SE, Wiersinga WM, et al: Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. J Clin Endocrinol Metab 1997; 82:4032-4036
45. Arem R, Wiener GJ, Kaplan SG, et al: Reduced tissue thyroid hormone levels in fatal illness. Metabolism 1993; 42:1102-1108
46. Spratt DI, Cox P, Orav J, et al: Reproductive axis suppression in acute illness is related to disease severity. J Clin Endocrinol Metab 1993; 76:1548-1554
47. Argenziano M, Choudhry AF, Oz MC, et al: A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997; 96(Suppl 9):286-290
48. Dunser MW, Mayr AJ, Ulmer H, et al: Arginine vasopressin in advanced vasodilatory shock: A prospective, randomized, controlled study. Circulation 2003; 107:2313-2319
49. Annane D, Bellissant E, Bollaert PE, et al: Corticosteroids for severe sepsis and septic shock: A systematic review and metaanalysis. BMJ 2004; 329:480
50. Keh D, Boehnke T, Weber-Cartens S, et al: Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: A double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003; 167:512-520
51. Maxime V, Fitting C, Annane D, et al: Corticoids normalize leukocyte production of macrophage migration inhibitory factor in septic shock. J Infect Dis 2005; 191:138-144
52. Annane D, Sebille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871
53. Ng PC, Lee CH, Bnur FL, et al: A doubleblind, randomized, controlled study of a "stress dose" of hydrocortisone for rescue treatment of refractory hypotension in preterm infants. Pediatrics 2006; 117:367-375
54. Van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359-1367
55. Van den Berghe G, Wilmer A, Hermans G, et al: Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354:449-461
56. Fowler RA, Annane D: The highs and lows of intensive insulin therapy. Am J Respir Crit Care Med 2006; 173:367-369
57. Stathatos N, Levetan C, Burman KD, et al: The controversy of the treatment of critically ill patients with thyroid hormone. Best Pract Res Clin Endocrinol Metab 2001; 15:465-478
58. Takala J, Ruokonen E, Webster NR, et al: Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341:785-792
59. Van den Berghe G, Baxter RC, Weekers F, et al: The combined administration of GHreleasing peptide-2 (GHRP-2), TRH, and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf) 2002; 56:655-669